Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using Quantitative Dot Blot (QDB) method

Junmei Hao, Yan Lv, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lv, Xunting Wang, View ORCID ProfileJiandi Zhang
doi: https://doi.org/10.1101/2020.03.11.20034439
Junmei Hao
1Dept. of Pathology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Lv
2Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics, Inc. (US), Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiarui Zou
1Dept. of Pathology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yunyun Zhang
2Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics, Inc. (US), Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuishan Xie
1Dept. of Pathology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lili Jing
1Dept. of Pathology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fangrong Tang
2Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics, Inc. (US), Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiahong Lv
2Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics, Inc. (US), Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xunting Wang
3Dept. of Imaging, Linglong Yingcheng Hospital, Zhaoyuan, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiandi Zhang
2Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics, Inc. (US), Yantai, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiandi Zhang
  • For correspondence: jiandi.zhang{at}outlook.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose The separation of Luminal A-like from Luminal B-like breast cancer subtypes in surrogate assay relies on Ki67 scores assessed by immunohistochemistry (IHC), a method known to be associated with subjectivity and inconsistency. We attempted to measure Ki67 levels absolutely, quantitatively and objectively in Formalin Fixed Paraffin Embedded (FFPE) specimens, and evaluate its influence on the performance of surrogate assay for breast cancer patients.

Methods The Ki67 protein levels were assessed using both IHC and Quantitative Dot Blot (QDB) methods respectively in 253 specimens. These patients were assigned into Luminal A-like and Luminal B-like subtypes using either Ki67 score of 14% as cutoff in surrogate assay, or 2.31 nmole/g from QDB method as cutoff in adjusted surrogate assay. These two subtyping methods were compared with the Kaplan-Meier, univariate and multivariate survival analyses of the overall survival (OS) of Luminal-like patients.

Results Ki67 levels measured using QDB method was highly correlated with those by IHC analysis (r=0.7, p<0.0001). The survival prediction for Luminal A-like patients was improved significantly in adjusted surrogate assay than surrogate assay (p=0.03 vs p<0.00052). The prediction of Hazard Ratio (HR) was also improve from 2.14 (95%CI: 0.89-5.11, p=0.087) to 6.89 (95%CI: 2.66-17.84, p<0.00001) in multivariate survival analysis.

Conclusion Our study demonstrated that the inherent subjectivity and inconsistency associated with IHC analysis has adverse effect on the performance of surrogate assay.

This issue can be improved by objective and quantitative measurement of Ki67 levels with QDB method in daily clinical practice.

Competing Interest Statement

YLv, WZ, FT, YZ, JLv & JZ are employees of Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics, Inc., who own or has filed patent applications for QDB plate, QDB method, & QDB application in IHC analysis. JH, JZou,SX, LJ, XW declared no conflict of interest

Funding Statement

This research is funded by Yantai Quanticision Diagnostics, Inc.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available upon request by writing to jiandi.zhang{at}outlook.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted March 16, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using Quantitative Dot Blot (QDB) method
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using Quantitative Dot Blot (QDB) method
Junmei Hao, Yan Lv, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lv, Xunting Wang, Jiandi Zhang
medRxiv 2020.03.11.20034439; doi: https://doi.org/10.1101/2020.03.11.20034439
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using Quantitative Dot Blot (QDB) method
Junmei Hao, Yan Lv, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lv, Xunting Wang, Jiandi Zhang
medRxiv 2020.03.11.20034439; doi: https://doi.org/10.1101/2020.03.11.20034439

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)